|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||169.64 - 172.67|
|52 Week Range||88.90 - 178.15|
|PE Ratio (TTM)||165.03|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||192.44|
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
PRA Health Sciences, just voted the Best CRO in Asia, may soon put its new buy point on trial.
The only "problem" mentioned by Vertex CEO Jeff Leiden? It's accumulating cash rapidly.
Vertex Pharmaceuticals Incorporated today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET.
NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Vertex Pharmaceuticals Incorporated today announced that it is initiating a Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have two copies of the F508del mutation, the most common genetic form of the disease.
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
Vertex Pharmaceuticals Incorporated today announced that Reshma Kewalramani, M.D., has been appointed Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, effective April 1, 2018.
Vertex could have a tripe-pill regimen in cystic fibrosis as early as 2019, analysts said Thursday after the biotech initiated the first of its Phase 3 studies.
Vertex Pharmaceuticals said Wednesday that the first late-stage trial of a potentially groundbreaking cystic fibrosis drug will be shorter than expected, prompting one analyst to forecast a possible FDA approval as early as the end of next year. Boston-based Vertex (VRTX) said after markets closed on Wednesday that it had launched the first of several Phase 3 studies of a “triple combination” treatment for cystic fibrosis. In a note on Thursday, Leerink Partners analyst Geoffrey Porges said he previously expected the FDA would require four to six months of safety data in a “best-case scenario” for the company, resulting in a possible approval in early 2020.
Vertex Pharmaceuticals Incorporated today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have one F508del mutation and one minimal function mutation.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Over the last one-month, outflows of investor capital in ETFs holding VRTX totaled $1.05 billion.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.